FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

1,276 letters match. Newest first.

  1. Sanofi

    FDA warned Sanofi subsidiary Genzyme over manufacturing quality failures at its Framingham, MA API plant.

    High risk
  2. www.weightcrunchshop.com

    FDA warned www.weightcrunchshop.com about selling unapproved and misbranded semaglutide and oxycodone drugs to U.S. consumers online.

    High risk
  3. Atlanta Supersource, Inc.

    Atlanta Supersource made OTC hand sanitizers on equipment shared with toxic industrial chemicals and lacked testing, FDA says.

    High risk
  4. INCELL Corporation LLC

    FDA warned INCELL Corporation for making an unapproved amniotic-fluid drug without validating its sterile manufacturing process.

    High risk
  5. Indoco Remedies Limited

    FDA warned Indoco Remedies over manufacturing quality failures at its Goa plant, including unreliable microbial testing and aseptic processing deficiencies.

    High risk
  6. Bhargava Phytolab Private Limited

    FDA warns Bhargava Phytolab over drug and API current good manufacturing practice (CGMP) violations, including inadequate testing and sterility controls.

    High risk
  7. Viatris, Inc.

    FDA warns Viatris that its Indore, India, drug plant had unreliable quality data and weak investigations.

    High risk
  8. Sombra Cosmetics, Inc.

    FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.

    High risk
  9. Akron Formulations India Private Limited

    Akron Formulations India's over-the-counter drugs are adulterated due to manufacturing quality (CGMP) failures, including unqualified active ingredient (API) suppliers and inadequate microbial testing.

    High risk
  10. Brands International Corporation

    Brands International, a Canadian drug manufacturer, limited an FDA inspection and had manufacturing quality violations including mold contamination.

    High risk
  11. Prime Vitality, Inc. dba Prime Peptides

    FDA warned Prime Peptides that its website sells Semaglutide and Retatrutide as unapproved new drugs for weight loss and diabetes.

    High risk
  12. Swisschems

    Swisschems sells Semaglutide and Retatrutide as unapproved new drugs despite research-chemical labeling.

    High risk
  13. Xcel Research LLC

    FDA warned Xcel Research for selling unapproved peptide drugs online with human-use claims.

    High risk
  14. Summit Research Peptides

    FDA warned Summit Research Peptides for selling unapproved semaglutide, retatrutide, cagrilintide, tirzepatide, and mazdutide with drug claims.

    High risk
  15. Veronvy

    FDA warned Veronvy that its Elily Veronvy weight-loss drops are unapproved new drugs and falsely labeled "FDA APPROVED."

    Medium
  16. Micro Orgo Chem

    Micro Orgo Chem in India failed CGMP for API drugs, including cleaning, process validation, stability and records.

    High risk
  17. Dr. Brite, LLC

    FDA cited Dr. Brite for manufacturing quality failures and selling unapproved, misbranded oral care and hand sanitizer drugs.

    High risk
  18. Guangzhou Four E’s Scientific Co., Ltd.

    FDA warns Guangzhou Four E’s over CGMP failures for OTC drugs, including a sterile-labeled product with inadequate sterility assurance.

    High risk
  19. Han C. Phan, M.D.

    FDA warns clinical investigator Dr. Han C. Phan over failure to follow a drug study’s protocol for required tests.

    Medium
  20. Applied Therapeutics, Inc.

    Applied Therapeutics, a trial sponsor, failed to let FDA access deleted electronic trial data and omitted dosing-error information from its drug application.

    High risk
  21. LCC Ltd.

    FDA warned LCC Ltd. over manufacturing-quality failures, contamination testing gaps, discarded lab data, and unapproved mouthwash drugs.

    High risk
  22. Zhejiang Uniquality Nursing Products Technology Co., Ltd. dba ZheJiang YouQuan Care Products Technology Co., Ltd.

    FDA warns Zhejiang Uniquality over inadequate OTC drug component testing and quality oversight; import alert issued.

    High risk
  23. Catwalk Cosmetic Laboratories Pty Ltd.

    FDA warns South African over-the-counter drug maker Catwalk Cosmetic Laboratories of current good manufacturing practice violations and import alert.

    High risk
  24. Eurosirel S.P.A

    FDA warns Eurosirel over CGMP failures in topical drugs and pain patches, including missing glycerin identity testing.

    High risk
  25. Hangzhou Huiji Biotechnology Co., Ltd.

    FDA warned Hangzhou Huiji Biotechnology over CGMP failures in OTC hand sanitizers, including missing glycerin and ethanol safety tests.

    High risk
  26. Centura Pharmaceuticals Inc

    FDA warned Centura Pharmaceuticals that its BLT 1-2-3 Cream, a mixed numbing product for cosmetic procedures, is an unapproved new drug.

    High risk
  27. Originitalia SRL

    FDA warns Originitalia SRL over manufacturing quality failures in OTC drugs, including untested active ingredient and missing release testing.

    High risk
  28. Richard W. Foltin, Ph.D.

    FDA warned sponsor Dr. Richard W. Foltin for starting drug trials in people without an IND.

    High risk
  29. Unexo Lifesciences, Private Limited

    FDA warned Unexo Lifesciences over serious CGMP violations, including data integrity failures and torn batch records for U.S.-bound drugs.

    High risk
  30. Colgate-Palmolive/Tom's of Maine, Inc.

    FDA cited Tom's of Maine for CGMP failures after finding objectionable microbes in water and toothpaste and inadequate complaint handling.

    High risk
  31. Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd.

    FDA cited Tianjin Darentang Jingwanhong Pharmaceutical for limiting a drug inspection and manufacturing violations at its China plant.

    High risk
  32. Zhejiang Qimei Cosmetics Co., Ltd.

    Zhejiang Qimei Cosmetics drew an FDA warning for CGMP violations in sterile-labeled OTC isopropyl alcohol prep pads.

    High risk
  33. Multaler et Cie SAS

    FDA cites Multaler et Cie for manufacturing failures and unapproved sunscreen after April 2024 inspection.

    High risk
  34. Armstrong County Memorial Hospital

    FDA warns Armstrong County Memorial Hospital review board over missing procedures and inadequate meeting minutes for drug research.

    Medium
  35. Fancy Drops Beauty LLC

    FDA says Fancy Drops Beauty sells unapproved eye drops claimed to change eye color.

    High risk
  36. Analytical Food Laboratories, Inc.

    FDA warned contract testing lab Analytical Food Laboratories after inspection found unvalidated drug test methods and weak quality oversight.

    High risk
  37. MedOffice Saglik Endustri Anonim Sirketi

    FDA warned MedOffice Saglik after an inspection found missing batch release testing and inadequate process validation for over-the-counter drugs.

    High risk
  38. Choice All Natural, Inc. dba Om Botanical

    FDA warns Om Botanical of Apex, NC over filthy manufacturing, an unapproved rash cream, and lapsed FDA registration.

    High risk
  39. Diora Kimya Sanayi ve Ticaret Limited Sirketi

    FDA cited Diora Kimya for drug manufacturing quality failures and for an unlisted antibacterial soap.

    High risk
  40. Soliteint Kozmetikai KFT

    Hungarian contract maker Soliteint Kozmetikai failed to test OTC pain-relief drugs and ingredients, FDA says; U.S. production halted.

    High risk
  41. Omni Lens Pvt. Ltd.

    FDA warns Omni Lens about CGMP failures and misbranding of ophthalmic OTC drugs made by unregistered contract manufacturers.

    High risk
  42. Stokes Healthcare Inc. dba Epicur Pharma

    Sterile compounding facility Epicur Pharma made drugs under insanitary conditions and with serious quality failures, FDA says.

    High risk
  43. Outin Futures Corp.

    FDA warned Outin Futures, a Korean drug manufacturer, of CGMP violations and sunscreen misbranding after a March 2024 inspection.

    High risk
  44. Mexicanrxpharm.com

    FDA told Mexicanrxpharm.com to stop selling unapproved, misbranded opioid pain drugs to U.S. consumers online.

    High risk
  45. Louisiana State University Health Science Center IRB

    FDA warns Louisiana State University Health Science Center IRB about missed continuing reviews and unreported study terminations for drug research.

    Medium
  46. MMC Healthcare Ltd.

    FDA warned MMC Healthcare Ltd. in Chennai that its drug products violate manufacturing rules, citing backdated records, weak computer controls, and unvalidated test methods.

    High risk
  47. Supercore Products Group, Inc.

    FDA warns Supercore that Hard Steel and Gold Hard Steel Plus are unapproved, mislabeled drugs with hidden sildenafil; Hard Steel also has acetaminophen.

    High risk
  48. Makra Kozmetika D.O.O.

    FDA warns Makra Kozmetika over OTC drug manufacturing violations, including missing batch and ingredient testing, after April 2024 inspection.

    High risk
  49. Little Moon Essentials, LLC

    FDA warns Little Moon Essentials over CGMP failures and unapproved topical analgesic drugs made in Dania Beach, Florida.

    High risk
  50. Diamond Chemical Co., Inc.

    Diamond Chemical Co. in East Rutherford, NJ, made OTC hand sanitizers without required ingredient and finished-product testing or process validation.

    High risk